“We are pleased to enter into our first global agreement for ALT-B4 with an experienced top pharmaceutical company,” said Dr. Soon Jae Park, Chief Executive Officer of Alteogen.

Under the terms of the agreement, Sandoz will acquire the world-wide rights to use ALT-B4, Alteogen’s novel hyaluronidase derived utilizing Hybrozyme™ Technology, to develop and commercialize ...